Qilian International Holding Group (BGM) Competitors $16.60 +0.25 (+1.53%) As of 09:34 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsHeadlinesSEC FilingsTrendsBuy This Stock BGM vs. ADMA, PCVX, MRUS, RYTM, AKRO, RNA, PTCT, CYTK, SRPT, and KRYSShould you be buying Qilian International Holding Group stock or one of its competitors? The main competitors of Qilian International Holding Group include ADMA Biologics (ADMA), Vaxcyte (PCVX), Merus (MRUS), Rhythm Pharmaceuticals (RYTM), Akero Therapeutics (AKRO), Avidity Biosciences (RNA), PTC Therapeutics (PTCT), Cytokinetics (CYTK), Sarepta Therapeutics (SRPT), and Krystal Biotech (KRYS). These companies are all part of the "pharmaceutical products" industry. Qilian International Holding Group vs. Its Competitors ADMA Biologics Vaxcyte Merus Rhythm Pharmaceuticals Akero Therapeutics Avidity Biosciences PTC Therapeutics Cytokinetics Sarepta Therapeutics Krystal Biotech ADMA Biologics (NASDAQ:ADMA) and Qilian International Holding Group (NASDAQ:BGM) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, valuation, media sentiment, analyst recommendations, profitability, earnings, dividends, community ranking and institutional ownership. Which has more risk and volatility, ADMA or BGM? ADMA Biologics has a beta of 0.47, meaning that its share price is 53% less volatile than the S&P 500. Comparatively, Qilian International Holding Group has a beta of 1.38, meaning that its share price is 38% more volatile than the S&P 500. Do analysts recommend ADMA or BGM? ADMA Biologics presently has a consensus price target of $24.25, suggesting a potential upside of 10.43%. Given ADMA Biologics' stronger consensus rating and higher possible upside, analysts plainly believe ADMA Biologics is more favorable than Qilian International Holding Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ADMA Biologics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25Qilian International Holding Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do insiders & institutionals believe in ADMA or BGM? 75.7% of ADMA Biologics shares are owned by institutional investors. 3.5% of ADMA Biologics shares are owned by insiders. Comparatively, 58.7% of Qilian International Holding Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Is ADMA or BGM more profitable? ADMA Biologics has a net margin of 17.80% compared to Qilian International Holding Group's net margin of 0.00%. ADMA Biologics' return on equity of 53.20% beat Qilian International Holding Group's return on equity.Company Net Margins Return on Equity Return on Assets ADMA Biologics17.80% 53.20% 26.07% Qilian International Holding Group N/A N/A N/A Does the MarketBeat Community favor ADMA or BGM? ADMA Biologics received 415 more outperform votes than Qilian International Holding Group when rated by MarketBeat users. CompanyUnderperformOutperformADMA BiologicsOutperform Votes41572.05% Underperform Votes16127.95% Qilian International Holding GroupN/AN/A Does the media refer more to ADMA or BGM? In the previous week, ADMA Biologics had 14 more articles in the media than Qilian International Holding Group. MarketBeat recorded 15 mentions for ADMA Biologics and 1 mentions for Qilian International Holding Group. Qilian International Holding Group's average media sentiment score of 1.89 beat ADMA Biologics' score of 0.72 indicating that Qilian International Holding Group is being referred to more favorably in the news media. Company Overall Sentiment ADMA Biologics Positive Qilian International Holding Group Very Positive Which has preferable earnings and valuation, ADMA or BGM? Qilian International Holding Group has lower revenue, but higher earnings than ADMA Biologics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioADMA Biologics$459.38M11.41-$28.24M$0.8525.84Qilian International Holding Group$25.10M64.30-$1.44MN/AN/A SummaryADMA Biologics beats Qilian International Holding Group on 11 of the 16 factors compared between the two stocks. Get Qilian International Holding Group News Delivered to You Automatically Sign up to receive the latest news and ratings for BGM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BGM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BGM vs. The Competition Export to ExcelMetricQilian International Holding GroupPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.61B$6.85B$5.57B$8.62BDividend YieldN/A2.55%5.28%4.18%P/E RatioN/A8.7827.1420.06Price / Sales64.30255.49419.32157.08Price / CashN/A65.8538.2534.64Price / Book2.726.557.064.70Net Income-$1.44M$143.93M$3.23B$247.88M7 Day Performance26.81%3.84%2.83%2.63%1 Month Performance45.42%11.20%9.02%6.36%1 Year PerformanceN/A4.18%31.36%14.05% Qilian International Holding Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BGMQilian International Holding GroupN/A$16.60+1.5%N/AN/A$1.61B$25.10M0.00298Positive NewsGap UpADMAADMA Biologics2.1842 of 5 stars$20.43+3.0%$24.25+18.7%+108.3%$4.88B$459.38M72.96530Insider TradeAnalyst RevisionPCVXVaxcyte2.8228 of 5 stars$35.02+7.8%$136.50+289.8%-51.2%$4.52BN/A-7.61160Analyst RevisionMRUSMerus3.1141 of 5 stars$58.53+4.4%$86.00+46.9%-3.6%$4.05B$54.73M-14.8237High Trading VolumeRYTMRhythm Pharmaceuticals4.1941 of 5 stars$63.66+3.8%$76.62+20.4%+61.6%$4.05B$136.86M-14.70140Insider TradeAKROAkero Therapeutics3.6396 of 5 stars$50.73+2.2%$82.50+62.6%+126.0%$4.04BN/A-13.5330Insider TradeOptions VolumeRNAAvidity Biosciences2.1688 of 5 stars$33.17+7.1%$66.38+100.1%+10.7%$4.00B$8.93M-11.52190Trending NewsAnalyst ForecastAnalyst RevisionPTCTPTC Therapeutics4.3445 of 5 stars$48.83+0.6%$63.75+30.6%+34.8%$3.87B$1.77B-8.221,410Analyst RevisionCYTKCytokinetics4.4258 of 5 stars$31.21+0.6%$73.71+136.2%-37.9%$3.73B$19.22M-5.80250Trending NewsAnalyst ForecastAnalyst RevisionSRPTSarepta Therapeutics4.8283 of 5 stars$37.74+0.4%$122.61+224.9%-68.8%$3.71B$2.23B30.19840Positive NewsKRYSKrystal Biotech4.689 of 5 stars$125.36-0.5%$211.13+68.4%-21.3%$3.62B$333.45M41.93210Positive NewsAnalyst Revision Related Companies and Tools Related Companies ADMA Competitors PCVX Competitors MRUS Competitors RYTM Competitors AKRO Competitors RNA Competitors PTCT Competitors CYTK Competitors SRPT Competitors KRYS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BGM) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | Sponsored2025 Market Crash50-Year Legend: Here's The Day Stocks Likely Crash Investing legend finds best cycle indicator during 50-ye...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Qilian International Holding Group Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Qilian International Holding Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
